Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.
作者信息
Chung Raymond T, Gale Michael, Polyak Stephen J, Lemon Stanley M, Liang T Jake, Hoofnagle Jay H
机构信息
Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
出版信息
Hepatology. 2008 Jan;47(1):306-20. doi: 10.1002/hep.22070.
Abstract
摘要
相似文献
1
Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.
Hepatology. 2008 Jan;47(1):306-20. doi: 10.1002/hep.22070.
2
Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
Nature. 2005 Aug 18;436(7053):967-72. doi: 10.1038/nature04082.
3
Hepatitis C virus: standard-of-care treatment.
Adv Pharmacol. 2013;67:169-215. doi: 10.1016/B978-0-12-405880-4.00005-6.
4
Virological response in post-partum treated chronic hepatitis C women with pegylated interferon-alpha plus ribavirin. A case-control study.
J Clin Virol. 2004 Dec;31(4):314-5. doi: 10.1016/j.jcv.2004.07.002.
5
Efficiency of second pegylated interferon and ribavirin combination treatment for the relapsed hepatitis C virus infection in low-income countries.
Eur J Gastroenterol Hepatol. 2014 Apr;26(4):493-4. doi: 10.1097/MEG.0000000000000054.
6
Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.
J Viral Hepat. 2008 Aug;15(8):571-7. doi: 10.1111/j.1365-2893.2008.00980.x. Epub 2008 Mar 24.
7
Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.
Medicina (Kaunas). 2018 Nov 5;54(5):80. doi: 10.3390/medicina54050080.
8
Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda.
Trans R Soc Trop Med Hyg. 2016 Aug;110(8):495-7. doi: 10.1093/trstmh/trw055. Epub 2016 Sep 12.
9
Non-responders to previous treatment for hepatitis C.
Minerva Gastroenterol Dietol. 2005 Mar;51(1):47-54.
10
Treatment of chronic viral hepatitis.
Acta Clin Belg. 1999 Oct;54(5):281-8. doi: 10.1080/17843286.1999.11754246.
引用本文的文献
1
Precision oncology through next generation sequencing in hepatocellular carcinoma.
Heliyon. 2025 Jan 17;11(3):e42054. doi: 10.1016/j.heliyon.2025.e42054. eCollection 2025 Feb 15.
2
Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV).
Expert Rev Anti Infect Ther. 2022 Nov;20(11):1413-1424. doi: 10.1080/14787210.2022.2125868. Epub 2022 Sep 20.
3
Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.
Viruses. 2022 May 25;14(6):1128. doi: 10.3390/v14061128.
4
A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis.
Gastroenterology Res. 2021 Jun;14(3):139-156. doi: 10.14740/gr1405. Epub 2021 Jun 19.
5
Host-Directed Antiviral Therapy.
Clin Microbiol Rev. 2020 May 13;33(3). doi: 10.1128/CMR.00168-19. Print 2020 Jun 17.
6
Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.
Sci Rep. 2020 Feb 7;10(1):2081. doi: 10.1038/s41598-020-58768-z.
7
Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations.
Graefes Arch Clin Exp Ophthalmol. 2019 Mar;257(3):447-452. doi: 10.1007/s00417-018-04209-7. Epub 2018 Dec 13.
8
Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues.
Ann Gastroenterol. 2018 Nov-Dec;31(6):670-679. doi: 10.20524/aog.2018.0306. Epub 2018 Sep 14.
9
Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population.
J Racial Ethn Health Disparities. 2018 Oct;5(5):1052-1058. doi: 10.1007/s40615-017-0453-y. Epub 2017 Dec 29.
10
A prediction model for the grade of liver fibrosis using magnetic resonance elastography.
BMC Gastroenterol. 2017 Nov 28;17(1):133. doi: 10.1186/s12876-017-0700-z.
本文引用的文献
1
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.
Hepatology. 2007 Nov;46(5):1548-63. doi: 10.1002/hep.21853.
2
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy.
J Virol. 2007 Aug;81(15):8211-24. doi: 10.1128/JVI.00487-07. Epub 2007 May 23.
3
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy.
Gastroenterology. 2007 May;132(5):1757-66. doi: 10.1053/j.gastro.2007.03.035. Epub 2007 Mar 24.
4
Keeping NK cells in highly regulated antiviral warfare.
Trends Immunol. 2007 Jun;28(6):252-9. doi: 10.1016/j.it.2007.04.001. Epub 2007 Apr 27.
5
Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor.
Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7253-8. doi: 10.1073/pnas.0611506104. Epub 2007 Apr 16.
6
Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy.
Gastroenterology. 2007 Mar;132(3):921-30. doi: 10.1053/j.gastro.2006.12.005. Epub 2006 Dec 3.
7
Specific targeted antiviral therapy for hepatitis C.
Curr Gastroenterol Rep. 2007 Mar;9(1):5-13. doi: 10.1007/s11894-008-0015-x.
8
The JAK-STAT signaling pathway: input and output integration.
J Immunol. 2007 Mar 1;178(5):2623-9. doi: 10.4049/jimmunol.178.5.2623.
9
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.
J Virol. 2007 Apr;81(7):3391-401. doi: 10.1128/JVI.02640-06. Epub 2007 Jan 31.
10
Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.
Gastroenterology. 2007 Feb;132(2):733-44. doi: 10.1053/j.gastro.2006.11.045. Epub 2006 Nov 29.
Zotero 插件